Invivyd (IVVD) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
19 May, 2026Opening remarks and agenda
Meeting called to order by the Chairman, with introductions of directors, legal counsel, and the independent auditor.
Virtual format enabled broader stockholder participation and access to agenda and procedures.
Stockholders instructed on question submission and voting procedures.
Board and executive committee updates
Six nominees for director were presented for election to serve one-year terms expiring at the 2027 annual meeting.
Shareholder proposals
Two proposals were presented: election of directors and ratification of the independent auditor.
No additional proposals were submitted in accordance with bylaws and applicable law.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Invivyd
- Q2 2026 revenue grew 21% but net loss widened, with future revenue at risk from PEMGARDA EUA expiry.IVVD
Q2 2026 - VYD2311 advances toward late-stage COVID-19 prevention, with broad pipeline and market ambitions.IVVD
H.C. Wainwright “HCW @ Home” Series - Antibody-based prevention aims to surpass vaccines in protection, safety, and patient preference.IVVD
Jefferies Global Healthcare Conference 2026 - PEMGARDA revenue up 22% YoY to $13.7M; net loss $41.4M; VYD2311 trial on track for Q3 data.IVVD
Q1 2026 - VYD2311 and VMS063 advance in pivotal COVID-19 and measles studies, targeting urgent unmet needs.IVVD
Study update - Shareholders will elect six directors and vote on auditor ratification at the 2026 annual meeting.IVVD
Proxy filing - Q3 revenue up 41% YoY to $13.1M, net loss narrowed, and pivotal VYD2311 trials set for year-end.IVVD
Q3 2025 - VYD2311 aims for durable, safe COVID protection with strong efficacy in pivotal prevention trials.IVVD
Study Update - Q2 PEMGARDA launch drove $2.3M revenue, but cash runway is under one year.IVVD
Q2 2024